These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30262843)

  • 21. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
    DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
    Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
    Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
    Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.
    Kriss CL; Pinilla-Ibarz JA; Mailloux AW; Powers JJ; Tang CH; Kang CW; Zanesi N; Epling-Burnette PK; Sotomayor EM; Croce CM; Del Valle JR; Hu CC
    Blood; 2012 Aug; 120(5):1027-38. PubMed ID: 22692508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
    Gorgun G; Ramsay AG; Holderried TA; Zahrieh D; Le Dieu R; Liu F; Quackenbush J; Croce CM; Gribben JG
    Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6250-5. PubMed ID: 19332800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
    Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
    Holler C; Piñón JD; Denk U; Heyder C; Hofbauer S; Greil R; Egle A
    Blood; 2009 Mar; 113(12):2791-4. PubMed ID: 19168795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
    Balatti V; Rizzotto L; Miller C; Palamarchuk A; Fadda P; Pandolfo R; Rassenti LZ; Hertlein E; Ruppert AS; Lozanski A; Lozanski G; Kipps TJ; Byrd JC; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2169-74. PubMed ID: 25646413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
    Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
    Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD74 is dispensable for development of chronic lymphocytic leukemia in
    Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
    Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21).
    Burlet B; Ramla S; Fournier C; Abrey-Recalde MJ; Sauter C; Chrétien ML; Rossi C; Duffourd Y; Ragot S; Buriller C; Tournier B; Chapusot C; Nadal N; Racine J; Guy J; Bailly F; Martin L; Casasnovas O; Bastie JN; Caillot D; Albuisson J; Broccardo C; Thieblemont C; Delva L; Maynadié M; Aucagne R; Callanan MB
    Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
    Walker JS; Hing ZA; Harrington B; Baumhardt J; Ozer HG; Lehman A; Giacopelli B; Beaver L; Williams K; Skinner JN; Cempre CB; Sun Q; Shacham S; Stromberg BR; Summers MK; Abruzzo LV; Rassenti L; Kipps TJ; Parikh S; Kay NE; Rogers KA; Woyach JA; Coppola V; Chook YM; Oakes C; Byrd JC; Lapalombella R
    J Hematol Oncol; 2021 Jan; 14(1):17. PubMed ID: 33451349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eμ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia.
    Fernandez Botana I; Gonder S; Klapp V; Moussay E; Paggetti J
    Methods Cell Biol; 2024; 188():109-129. PubMed ID: 38880520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.
    Prinz C; Vasyutina E; Lohmann G; Schrader A; Romanski S; Hirschhäuser C; Mayer P; Frias C; Herling CD; Hallek M; Schmalz HG; Prokop A; Mougiakakos D; Herling M
    Mol Cancer; 2015 Jun; 14():114. PubMed ID: 26041471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia.
    Parigger T; Gassner FJ; Scherhäufl C; Bakar AA; Höpner JP; Hödlmoser A; Steiner M; Catakovic K; Geisberger R; Greil R; Zaborsky N
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic alterations in a murine model for chronic lymphocytic leukemia.
    Chen SS; Sherman MH; Hertlein E; Johnson AJ; Teitell MA; Byrd JC; Plass C
    Cell Cycle; 2009 Nov; 8(22):3663-7. PubMed ID: 19901553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
    Lewis R; Maurer HC; Singh N; Gonzalez-Menendez I; Wirth M; Schick M; Zhang L; Isaakidis K; Scherger AK; Schulze V; Lu J; Zenz T; Steiger K; Rad R; Quintanilla-Martinez L; Espeli M; Balabanian K; Keller U; Habringer S
    Leukemia; 2021 Oct; 35(10):2895-2905. PubMed ID: 34363012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts.
    Davies NJ; Kwok M; Gould C; Oldreive CE; Mao J; Parry H; Smith E; Agathanggelou A; Pratt G; Taylor AMR; Moss P; Griffiths M; Stankovic T
    Oncotarget; 2017 Jul; 8(27):44749-44760. PubMed ID: 28496009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.
    Pekarsky Y; Palamarchuk A; Maximov V; Efanov A; Nazaryan N; Santanam U; Rassenti L; Kipps T; Croce CM
    Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19643-8. PubMed ID: 19064921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice.
    Collard JP; McKenna MK; Noothi SK; Alhakeem SS; Rivas JR; Rangnekar VM; Muthusamy N; Bondada S
    Leuk Lymphoma; 2022 Aug; 63(8):1810-1822. PubMed ID: 35258388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.